Loading...
•
Jun 30, 2023
The Joint Q2 2023 Earnings Report
The Joint Corp. reported preliminary financial results with revenue and Adjusted EBITDA growth compared to the prior year period.
Key Takeaways
The Joint Corp. reported preliminary Q2 2023 revenue of $29.3 million, an 18% increase compared to Q2 2022. Preliminary Adjusted EBITDA was $3.2 million, a 23% increase compared to Q2 2022. The company is evaluating programs to cull approximately 10% of the corporate portfolio to improve profitability.
Preliminary revenue increased by 18% compared to Q2 2022, reaching $29.3 million.
Preliminary Adjusted EBITDA increased by 23% compared to Q2 2022, totaling $3.2 million.
The company is focusing on improving clinic performance and overall profitability through various strategies.
Evaluating programs to cull approximately 10% of the corporate portfolio.
Forward Guidance
The company provided preliminary amended financial guidance to reflect the preliminary second quarter financial results, new accounting procedures, current economic environment, and other factors. The company reiterated the clinic opening guidance.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...